83 related articles for article (PubMed ID: 38200591)
1. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
Ma Z; Zhou Z; Duan W; Yao G; Sheng S; Zong S; Zhang X; Li C; Liu Y; Ou F; Dahar MR; Huang Y; Yu L
Cancer Immunol Immunother; 2024 Mar; 73(5):82. PubMed ID: 38554200
[TBL] [Abstract][Full Text] [Related]
2. Cancer-associated fibroblasts influence Wnt/PCP signaling in gastric cancer cells by cytoneme-based dissemination of ROR2.
Rogers S; Zhang C; Anagnostidis V; Liddle C; Fishel ML; Gielen F; Scholpp S
Proc Natl Acad Sci U S A; 2023 Sep; 120(39):e2217612120. PubMed ID: 37722040
[TBL] [Abstract][Full Text] [Related]
3. Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination.
Ogawa H; Abe H; Yagi K; Seto Y; Ushiku T
Gastric Cancer; 2024 May; ():. PubMed ID: 38724721
[TBL] [Abstract][Full Text] [Related]
4. Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys.
Wang J; Dong T; Gong X; Li D; Sun J; Luo Y; Wu H
Int J Toxicol; 2024; 43(3):291-300. PubMed ID: 38115178
[TBL] [Abstract][Full Text] [Related]
5. CLDN18: Clinical, Pathological, and Genetic Signatures with Drug Screening in Gastric Adenocarcinoma.
Hur JY; Min KW; Noh YK; Won YW; Yeo Y; Kim DH; Son BK; Kwon MJ; Pyo JS
Curr Med Chem; 2024 Apr; ():. PubMed ID: 38639279
[TBL] [Abstract][Full Text] [Related]
6. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.
Rogers JE; Ajani J
Curr Oncol; 2024 Feb; 31(2):769-777. PubMed ID: 38392051
[TBL] [Abstract][Full Text] [Related]
7. State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.
Rogers JE; Ajani JA
Curr Opin Oncol; 2024 Apr; ():. PubMed ID: 38726797
[TBL] [Abstract][Full Text] [Related]
8.
Qi C; Guo R; Chen Y; Li C; Liu C; Zhang M; Zhang C; Zhang X; Hou X; Chen B; Jia B; Yang Z; Shen L; Zhu H
J Nucl Med; 2024 Apr; ():. PubMed ID: 38604764
[No Abstract] [Full Text] [Related]
9. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.
Zhang F; Sahu V; Peng K; Wang Y; Li T; Bala P; Aitymbayev D; Sahgal P; Schaefer A; Der CJ; Ryeom S; Yoon S; Sethi N; Bass AJ; Zhang H
Gut; 2024 Apr; ():. PubMed ID: 38621923
[TBL] [Abstract][Full Text] [Related]
10. Claudins in Cancer: A Current and Future Therapeutic Target.
Hana C; Thaw Dar NN; Galo Venegas M; Vulfovich M
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731853
[TBL] [Abstract][Full Text] [Related]
11. Signaling, cancer cell plasticity, and intratumor heterogeneity.
Cordani M; Dando I; Ambrosini G; González-Menéndez P
Cell Commun Signal; 2024 May; 22(1):255. PubMed ID: 38702718
[TBL] [Abstract][Full Text] [Related]
12. Influential upregulation of KCNE4: Propelling cancer associated fibroblasts-driven colorectal cancer progression.
Zhang Z; Liu S; Wang Z; Wang S; Jiang L; Wang X; Li J; Shen L
Cancer Cell Int; 2024 Mar; 24(1):103. PubMed ID: 38462626
[TBL] [Abstract][Full Text] [Related]
13. Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
Matsusaka K; Ushiku T; Urabe M; Fukuyo M; Abe H; Ishikawa S; Seto Y; Aburatani H; Hamakubo T; Kaneda A; Fukayama M
Oncotarget; 2016 Sep; 7(39):64168-64181. PubMed ID: 27580354
[TBL] [Abstract][Full Text] [Related]
14. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
[TBL] [Abstract][Full Text] [Related]
15. Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells.
Ishimoto T; Miyake K; Nandi T; Yashiro M; Onishi N; Huang KK; Lin SJ; Kalpana R; Tay ST; Suzuki Y; Cho BC; Kuroda D; Arima K; Izumi D; Iwatsuki M; Baba Y; Oki E; Watanabe M; Saya H; Hirakawa K; Baba H; Tan P
Gastroenterology; 2017 Jul; 153(1):191-204.e16. PubMed ID: 28390866
[TBL] [Abstract][Full Text] [Related]
16. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion.
Angerilli V; Ghelardi F; Nappo F; Grillo F; Parente P; Lonardi S; Luchini C; Pietrantonio F; Ugolini C; Vanoli A; Fassan M
Pathol Res Pract; 2024 Feb; 254():155145. PubMed ID: 38277741
[TBL] [Abstract][Full Text] [Related]
17. Claudins and Gastric Cancer: An Overview.
Hashimoto I; Oshima T
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053454
[TBL] [Abstract][Full Text] [Related]
18. Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression.
Liu S; Zhang Z; Jiang L; Zhang M; Zhang C; Shen L
Cell Commun Signal; 2024 Jan; 22(1):27. PubMed ID: 38200591
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
